Eyenovia, Inc. EYEN
Set alert
As of Oct 20, 12:58 PM ET
52-week range unavailable
- YTD
- -35.27%
- 1 year
- -87.28%
- Open
- 7.54
- Prev close
- 7.56
- Mkt cap
- 9.42M
- Vol
- 29.50K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.28
- High
- 7.82
- Forward P/E
- -0.16
- Beta
- 1.75
- Short ratio
- 2.45
- Inst. own
- 13.73%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 0.2981
- 200-d avg
- 0.679655
- 1y target
- 3.50
2Y chart
Events in this range
- Mar 18, 2024Earnings: —; estimate -0.17; surprise —%
- May 15, 2024Earnings: -0.18; estimate -0.18; surprise 0%
- May 15, 2024Earnings: —; estimate -0.18; surprise —%
- Aug 12, 2024Earnings: -0.18; estimate -0.17; surprise -5.88%
- Aug 12, 2024Earnings: —; estimate -0.17; surprise —%
- Aug 13, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Nov 12, 2024Earnings: -0.11; estimate -0.13; surprise 15.38%
- Nov 13, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Nov 15, 2024Downgrade: Brookline Capital · Buy → Hold
- Nov 15, 2024Downgrade: William Blair · Outperform → Market Perform
- Nov 18, 2024Downgrade: HC Wainwright & Co. · Buy → Neutral
- Nov 18, 2024Downgrade: Ladenburg Thalmann · Buy → Neutral
- Feb 3, 2025Split: 1 for 80
Signals (73)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Jun 27, 2025 | 1 year ago |
| RSI: Overbought | Jun 24, 2025 | 1 year ago |
| RSI: Overbought | Jun 17, 2025 | 1 year ago |
| RSI: Overbought | Jun 5, 2025 | 1 year ago |
| RSI: Overbought | May 22, 2025 | 1 year ago |
| SMA: Bullish | May 20, 2025 | 1 year ago |
| RSI: Overbought | May 20, 2025 | 1 year ago |
| RSI: Oversold | Mar 21, 2025 | 1 year ago |
| RSI: Oversold | Mar 3, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 10, 2025 | 1 year ago |
| RSI: Oversold | Feb 5, 2025 | 1 year ago |
| RSI: Oversold | Jan 31, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 21, 2025 | 1 year ago |
| RSI: Oversold | Dec 20, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 5, 2024 | 1 year ago |
| RSI: Oversold | Nov 14, 2024 | 1 year ago |
| SMA: Bearish | Nov 13, 2024 | 1 year ago |
| SMA: Bullish | Nov 12, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 6, 2024 | 1 year ago |
| SMA: Bearish | Nov 5, 2024 | 1 year ago |
Newest 20 of 73.
Key statistics
- Market cap
- 9.42M
- Enterprise value
- 39.47M
- Trailing P/E
- 0.00
- Forward P/E
- -0.16
- PEG ratio
- 0.00
- Price / sales
- 299.81
- Price / book
- 0.43
- EPS (TTM)
- -0.69
- Beta
- 1.75
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 31.41K
- Revenue growth
- 0.00%
- Free cash flow
- -18.18M
- Total cash
- 2.30M
- Total debt
- 15.66M
- Return on equity
- -914.66%
- Shares outstanding
- 111.42M
- Short % of float
- 2.68%
- 50-day average
- 0.2981
- 200-day average
- 0.679655
Analyst view
Consensus: none
- Target (low)
- 2.00
- Target (mean)
- 3.50
- Target (high)
- 5.00
- Strong buy0
- Buy0
- Hold3
- Sell0
- Strong sell0
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate -0.09.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.13 | -0.11 | +0.02 | +15.38% |
| Aug 12, 2024 | Jun 1, 2024 | -0.17 | -0.18 | -0.01 | -5.88% |
| Aug 12, 2024 | Jun 1, 2024 | -0.17 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | -0.18 | -0.18 | 0.00 | 0.00% |
| May 15, 2024 | Mar 1, 2024 | -0.18 | — | — | — |
| Mar 18, 2024 | Dec 1, 2023 | -0.17 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 18, 2024 | Ladenburg Thalmann | down | Buy | Neutral |
| Nov 18, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| Nov 15, 2024 | William Blair | down | Outperform | Market Perform |
| Nov 15, 2024 | Brookline Capital | down | Buy | Hold |
| Nov 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Eyenovia, Inc.
Eyenovia, Inc., a commercial-stage ophthalmic pharmaceutical technology company, engages in developing a pipeline of microdose array print therapeutics. It focuses on commercializing Mydcombi (tropicamide and phenylephrine HCL ophthalmic spray) for inducing mydriasis for routine diagnostic procedures and in conditions where short term pupil dilation is desired, and clobetasol propionate ophthalmic suspension for the treatment of post-operative pain and inflammation following ocular surgery. The company is also developing the Optejet delivery system for use in combination with its drug-device therapeutic programs and for out-licensing for use in combination with therapeutics for additional indications. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company has agreement with Formosa Pharmaceuticals. Inc. for Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- eyenovia.com
News
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- 12 Health Care Stocks Moving In Friday's Intraday Session
- Crude Oil Moves Higher; US Weekly Jobless Claims Decline
- Chardan Expands into Digital Assets by Advising Strategic Crypto-Backed Financings
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Dow Surges 150 Points; Korn Ferry Earnings Top Views
- Eyenovia Announces Appointment of a Strategic Advisor for Digital Asset Treasury Strategy and Amendment of Debt Agreement with Avenue Capital Group
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
Your note
Sign in to keep a note on EYEN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GANDOLFO JOHN P | Chief Financial Officer | Purchase | May 30, 2023 | 8,000 |
| GELTZEILER MICHAEL S | Director | Stock Award(Grant) | Jun 11, 2024 | 81,295 |
| GRANT STUART M | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jul 1, 2024 | 6,971,790 |
| IANCHULEV TSONTCHO | Director | Stock Award(Grant) | Jun 11, 2024 | 1,022,600 |
| JACOBSON RACHEL | Director | Stock Award(Grant) | Jun 11, 2024 | 104,233 |
| KERN BREN | Chief Operating Officer | Purchase | May 25, 2023 | 2,500 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 7.66% | 8,534,347 | 721.15K | Sep 29, 2024 |
| Vanguard Group Inc | 1.69% | 1,881,290 | 158.97K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.50% | 557,994 | 47.15K | Sep 29, 2024 |
| Lasry, Marc | 0.49% | 547,807 | 46.29K | Sep 29, 2024 |
| Millennium Management Llc | 0.35% | 388,114 | 32.80K | Sep 29, 2024 |
| Diametric Capital, Lp | 0.14% | 157,966 | 13.35K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.28% | 1,425,221 | 120.43K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.39% | 430,389 | 36.37K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.26% | 289,667 | 24.48K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.08% | 85,524 | 7.23K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.08% | 87,366 | 7.38K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.06% | 70,304 | 5.94K | Oct 30, 2024 |